Hyperpituitarism: Clinical Trials

23 trials for Hyperpituitarism, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

23 completed. 23 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 423Completed 23

Follow Hyperpituitarism: new trials by email Literature Review of Hyperpituitarism trials Research Report on Hyperpituitarism

Trials (filtered) newest first · largest first

All 23 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
Pasireotide s.c., Sitagliptin, Liraglutide - Cushing's Disease, Acromegaly
Phase 4CompletedNovartis Pharmaceuticals2492014-05-232019-05-29
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
Pasireotide, Cabergoline, Pasireotide LAR - Cushing's Disease, Acromegaly
Phase 4CompletedRECORDATI GROUP3372013-06-102024-10-01
Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment
Pasireotide 0.6 MG/ML - Cushing Disease
Phase 4CompletedUniversity of Palermo242013-05-012017-10-27
Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target
SandostatinĀ® LAR - Acromegaly
Phase 4CompletedUniversity of Aarhus842012-06-012017-01-26
Aripiprazole and Prolactin Study
Aripiprazole - Hyperprolactinemia
Phase 4CompletedUniversity of Oxford152010-04-012015-05-28
Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects
Lanreotide Autogel 120 mg - Acromegaly
Phase 4CompletedIpsen1242008-10-012019-01-29
Endometriosis Patients Undergoing Quinagolide Treatment
ENDOMETRIAL BIOPSY - Hyperprolactinemia, Endometriosis
Phase 4CompletedInstituto Valenciano de Infertilidad, IVI VALENCIA52008-02-012009-01-12
Acute Application of Pegvisomant and Octreotide in Acromegaly
pegvisomant, combination with somatostatin analogue octreotide, combination with dopamine agonist cabergoline - Acromegaly
Phase 4CompletedLudwig-Maximilians - University of Munich102008-01-012008-04-01
Ultrasound Guided Octreotide LAR Injection in Acromegaly
Octreotide LAR 30 MG Injection - Acromegaly
Phase 4CompletedCedars-Sinai Medical Center152007-07-012018-09-11
Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients
Pegvisomant - Quality of Life, Acromegaly
Phase 4CompletedErasmus Medical Center202006-10-012008-03-25
Effects of Sandostatin LARĀ® in Acromegaly
Sandostatin LAR - Acromegaly
Phase 4CompletedColumbia University212006-10-012024-07-24
Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
Sandostatin LAR, pegvisomant, cabergoline - Acromegaly
Phase 4CompletedNovartis Pharmaceuticals702006-09-012017-03-03
Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
Octreotide acetate and cabergoline/Octrotide and Somavert - Acromegaly
Phase 4CompletedNovartis Pharmaceuticals202006-03-012017-03-06
Canadian Pegvisomant Compassionate Study In Acromegalic Patients
Pegvisomant treatment, Medical History, demographics, Sign and symptoms: questionnaire - Acromegaly
Phase 4CompletedPfizer302004-11-012008-04-24
Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
Lanreotide (Autogel formulation) - Acromegaly
Phase 4CompletedIpsen82004-06-012019-08-16
Somatuline Autogel: Acromegaly Self/Partner Injection Study
Lanreotide (Autogel formulation) - Acromegaly
Phase 4CompletedIpsen302004-02-012019-08-05
Pegvisomant And Sandostatin LAR Combination Study
Pegvisomant/ Sandostatin LAR, Sandostatin LAR, Pegvisomant - Acromegaly
Phase 4CompletedPfizer752003-10-012008-04-07
A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly
Pegvisomant, Sandostatin LAR - Acromegaly
Phase 4CompletedPfizer1002003-04-012008-04-07
Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly
Lanreotide-Autogel 120 mg - Acromegaly
Phase 4CompletedFederico II University272003-01-012008-03-03
Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction
Lanreotide Autogel and Octreotide LAR - Acromegaly
Phase 4CompletedOdense University Hospital122002-09-012006-09-08

Showing 20 of 23. Sign in to see all of them.

Narrower conditions

Acromegaly (20)  ·  Pituitary ACTH Hypersecretion (3)  ·  Pituitary Neoplasms (3)  ·  Hyperprolactinemia (2)  ·  Neoplasms (2)  ·  Brain Neoplasms (1)  ·  Dumping Syndrome (1)  ·  Endometriosis (1)  ·  Hyperglycemia (1)  ·  Hypogonadism (1)  ·  Melanoma (1)  ·  Neuroendocrine Tumors (1)  ·  Prostatic Neoplasms (1)

Broader conditions

Brain Diseases (23)  ·  Central Nervous System Diseases (23)  ·  Endocrine System Diseases (23)  ·  Hypothalamic Diseases (23)  ·  Nervous System Diseases (23)  ·  Pituitary Diseases (23)  ·  Bone Diseases (20)  ·  Bone Diseases, Endocrine (20)  ·  Musculoskeletal Diseases (20)  ·  Central Nervous System Neoplasms (3)  ·  Endocrine Gland Neoplasms (3)  ·  Hypothalamic Neoplasms (3)  ·  Neoplasms by Site (3)  ·  Nervous System Neoplasms (3)

Interventions

pegvisomant (6)  ·  Octreotide (4)  ·  Cabergoline (3)  ·  lanreotide (3)  ·  pasireotide (3)  ·  Aripiprazole (1)  ·  Demography (1)  ·  Glucose Tolerance Test (1)  ·  Health Records, Personal (1)  ·  Injections (1)  ·  Insulin (1)  ·  Liraglutide (1)  ·  Metformin (1)  ·  Sitagliptin Phosphate (1)

Sponsors

Novartis Pharmaceuticals (4)  ·  Ipsen (3)  ·  Pfizer (3)  ·  Federico II University (2)  ·  Cedars-Sinai Medical Center (1)  ·  Columbia University (1)  ·  Erasmus Medical Center (1)  ·  Instituto Valenciano de Infertilidad, IVI VALENCIA (1)  ·  Ludwig-Maximilians - University of Munich (1)  ·  Odense University Hospital (1)  ·  RECORDATI GROUP (1)  ·  St. Olavs Hospital (1)  ·  University of Aarhus (1)  ·  University of Oxford (1)  ·  University of Palermo (1)

Countries

Germany (6)  ·  Italy (6)  ·  United States (6)  ·  Brazil (5)  ·  France (5)  ·  Spain (5)  ·  Canada (4)  ·  Denmark (4)  ·  Norway (4)  ·  Poland (4)  ·  United Kingdom (4)  ·  Australia (3)  ·  Greece (3)  ·  Netherlands (3)  ·  Russia (3)

Top investigators

Annamaria AL Colao, Prof. (1)  ·  Annamaria Colao, MD, PhD (1)  ·  Guy M Goodwin, PhD (1)  ·  Jochen Schopohl, MD (1)  ·  John Carmichael, MD (1)  ·  Marianne Andersen, MD, PhD (1)  ·  Pamela U Freda, MD (1)  ·  Sven M Carlsen, MD, PhD (1)

Results publications

PMID 15613435, PMID 15827109, PMID 10469005, PMID 10690849, PMID 10999798, PMID 11397887, PMID 11788630, PMID 12843148, PMID 14764779, PMID 15070920, PMID 15080776, PMID 15080778, PMID 15099442, PMID 15362960, PMID 15886238, PMID 15886256, PMID 16373932, PMID 16449332, PMID 16487447, PMID 16537687, PMID 16918950, PMID 17259801, PMID 17555511, PMID 17892497, PMID 17984237, PMID 18492760, PMID 19094074, PMID 20003832, PMID 21055747, PMID 21521254, PMID 24092547, PMID 24866574, PMID 27405306, PMID 34275099, PMID 3899825, PMID 5427331, PMID 8050136, PMID 8327647, PMID 8514973, PMID 9709939, PMID 9768640, PMID 9768641, PMID 9808008

NIH funding

2005 (1), 2009 (1)